Indeed, the value of diagnostic biomarkers is clearly seen in the utility of detecting thyroglobulin for monitoring thyroid cancer, and in administering Herceptin specifically for breast cancers overexpressing HER2/neu [4]. Here, ERBB2 is linked to breast carcinoma.